Listen to our newest podcast with Ruth Marinshaw, CTO of Research Computing at Stanford University.

Close this search box.

Kim Branson on Building Groundbreaking AI/ML Models in Drug Discovery

Trends Episode005 Branson

Dr. Kim Branson’s intense interest in drug discovery and structural biology quickly led to an interest in machine learning. After receiving multiple degrees from esteemed universities in Australia, Branson trained at Stanford and now works as the Senior Vice President and Global Head of AI/ML at GSK. With host and BioTeam’s co-founder, Stan Gloss, Branson shares his work in creating “biological twins.” These 3-D tumor culture models replicate cancer and their respective immune environments. Branson and his team monitor tumor and immune responses to cancer drugs in real-time. The clinical implications of anticipating a tumor’s every move within a patient’s body are astounding. He also explains why thoughtfulness is paramount in experiment design and how a project’s impact should be the primary consideration before proceeding. Learn how GSK recruits talent and the importance of creating a multidisciplinary environment. Hear Branson talk about eliminating AI analysis bias, navigating ethical issues, and the new generation of leaders on his team. 



Get updates from BioTeam in your inbox.

Trends from the Trenches eBook January 2022

The eBook of BioTeam and Bio-IT World's Most Trending Articles